VoxelCloud Unveils Full-Disease AI Strategy at China's First Medical Imaging AI Conference, Announces Strategic Partnerships with Lunren Medical Group and Synyi Intelligence
VCBeat (WeChat ID: vcbeat) has learned that on December 15, 2018, the inaugural China Medical Imaging AI Conference grandly opened at the Shanghai National Convention Center. As the initiator of a comprehensive AI product portfolio covering all disease categories in the “AI + Healthcare” sector and a leading global artificial intelligence enterprise, VoxelCloud held a press conference at the event to announce the strategic upgrade of its all-disease AI product portfolio. The company unveiled its comprehensive strategies for chest CT, ophthalmology, and dermatology product lines, strengthened in-depth collaboration with the Industry-Academia-Research-Application AI Alliance, committed itself to the R&D of products covering all disease categories, and contributed to the establishment of industry standards for multi-task learning. Additionally, VoxelCloud announced the formation of strategic partnerships with Lunxun Doctor Group and Senyi Intelligence.
In the future, VoxelTech will leverage the expertise and technical strengths of industry associations in the AI sector, physician groups, and strategic partners to optimize clinical workflow integration, expand application scenarios, and accelerate the diversified R&D and deployment efficiency of its products. This aims to swiftly realize the vision of making diagnoses more accurate and timely.
Professor Liu Shiyuan, Chairman-Elect of the Chinese Society of Radiology, Chairman of the China Medical Imaging AI Industry-Academia-Research-Application Innovation Alliance, and Director of the Department of Diagnostic Radiology and Nuclear Medicine at Shanghai Changzheng Hospital; Professor Li Ke, Chief Medical Advisor at Roentgen Medical; Ma Handong, Co-founder of Senyi Intelligence; and other distinguished experts and guests attended the event, joining Ding Xiaowei, Founder and CEO of VoxelCloud, to jointly launch the strategic upgrade of VoxelCloud’s comprehensive AI product portfolio for all disease categories.
Voxel Technology Launch Ceremony for the Strategic Upgrade of Its AI-Powered Pan-Disease Product Portfolio
The field of artificial intelligence (AI) has witnessed rapid development in recent years. VoxelCloud, established over two years ago, is one of the earliest teams to engage in AI-based medical imaging research and a pioneer in developing comprehensive, all-disease AI solutions for the healthcare industry. In its auxiliary diagnosis product line, VoxelCloud focuses on four comprehensive disease-specific solutions: chest CT, color fundus photography, coronary CTA, and dermatology. Additionally, the company holds a leading position in technologies that assist diagnosis through analysis of patient behavior in videos, such as for pediatric visual impairments. By categorizing AI medical products according to clinical scenarios, VoxelCloud better aligns with the practical needs of healthcare institutions.
From the perspective of clinical medical practice, standalone pulmonary nodule screening is insufficient to meet physicians' clinical needs. During chest CT examinations, pulmonary nodule screening constitutes only one component of the diagnostic requirements. Conditions such as pneumonia, pulmonary bullae, interstitial lung diseases, heart disease, pleural effusion, and bronchiectasis, along with the phenomenon of "different diseases presenting with similar imaging features" and "the same disease manifesting with diverse imaging appearances," still necessitate manual interpretation and resolution from scratch.
Unlike the plethora of pulmonary nodule screening products flooding the market, VoxelCloud’s comprehensive chest CT solution for multiple diseases addresses a wide range of common conditions and lesion types detectable by chest CT. This broader scope will lead to greater clinical adoption, allowing the technology to truly integrate into physicians’ workflows and provide substantial assistance in diagnostic decision-making. Professor Liu Shiyuan stated that multi-task, multi-disease development is the goal of AI products. He believes that artificial intelligence will grant physicians greater freedom and possibilities in the future, and he looks forward to VoxelCloud’s comprehensive disease-management system providing meaningful support to clinicians.
Professor Liu Shiyuan Delivers Keynote Address on “Current Status and Challenges of AI R&D in Medical Imaging in China”
In the field of ophthalmic products, Voxel Technology’s comprehensive screening solution for all retinal diseases also stands apart from similar offerings in the industry. By combining fundus photography with patient information, this product enables comprehensive screening for major chronic fundus diseases, including diabetic retinopathy, diabetic macular edema, glaucoma, cataracts, and age-related macular degeneration, while also providing early warnings for other lesions, thereby achieving truly comprehensive coverage of fundus diseases. Patients can undergo a full screening for various fundus conditions with just a single fundus photograph, which holds significant clinical value for hospital ophthalmology and endocrinology departments, as well as health examination centers.
At the conference, Voxel Technology also showcased its all-in-one hardware and software solution for comprehensive ophthalmic disease management. The fully automated operation, combined with an automated image interpretation system, has significantly reduced staff workload. Currently, Voxel Technology’s comprehensive ophthalmic product line has been initially deployed at National Standardized Metabolic Disease Management Centers (MMC) and is now available in over 100 MMC centers across hospitals in China.
The “AI Triage for All Skin Conditions” product line includes VoxelCloud’s latest release, “VoxelDerm Insight,” the first public-facing, intelligent assessment solution for a comprehensive range of skin conditions in China and worldwide. Leveraging deep learning-based image analysis and processing technology, it fully integrates VoxelCloud’s technical strengths in medical imaging with millions of image and text data points from mobile remote dermatology consultations. By harnessing AI’s ability to abstract and extract features and consolidate specialized dermatological knowledge, the solution provides comprehensive intelligent recognition and analysis of skin lesions, enabling intelligent matching and assessment for hundreds of skin diseases, thus serving as an effective AI tool for pre-consultation triage.
Ding Xiaowei, Founder and Co-CEO of Voxel Technology
At the press conference, Voxel Technology entered into strategic partnerships with Roentgen Doctors Group and Senyi Intelligence, respectively, and signed contractual agreements. Voxel Technology reached a consensus with Roentgen Doctors Group to establish a long-term, stable collaborative relationship that promotes the integration of industry, academia, and research. By effectively leveraging clinical technical expertise to drive technological R&D and enhance product application, both parties will jointly explore cooperative models for the application of AI products in imaging-related fields, including radiology departments, independent imaging diagnostic centers, and remote medical diagnostics.
Additionally, VoxelCloud has partnered with Senyi Intelligence to develop an AI-powered imaging and single-disease intelligent research database solution. Leveraging its advanced artificial intelligence algorithms for chest CT and other imaging protocols, VoxelCloud performs batch processing of extensive historical and newly acquired patient imaging data. It extracts quantitative and qualitative parameters valuable for clinical practice and scientific research, including lesion type, size, location, radiological signs, and longitudinal follow-up comparisons. By integrating physicians’ diagnostic information with Senyi Intelligence’s proprietary comprehensive disease-specific data solution, the data is structured and standardized while ensuring data security and quality. This facilitates the establishment of a true single-disease database, enabling functionalities such as intelligent retrieval, data imputation, data export, and statistical analysis. The solution achieves cross-departmental data integration throughout the entire diagnosis and treatment workflow, maximizing the usability of specialty-specific data. It effectively supports hospitals in leveraging big data for clinical research, clinical diagnosis and treatment, and medical administration, thereby enhancing clinical decision support services and academic research capabilities.